Get the Stockscreener App
18.93
0.64%
-0.1539
Zymeworks Inc. stock is traded at $18.93, with a volume of 41,953.
It is down -0.64% in the last 24 hours and up +11.94% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$19.09
Open:
$19
24h Volume:
41,953
Relative Volume:
0.07
Market Cap:
$1.42B
Revenue:
$122.87M
Net Income/Loss:
$-73.68M
P/E Ratio:
-19.31
EPS:
-0.9803
Net Cash Flow:
$-39.27M
1W Performance:
+2.66%
1M Performance:
+11.94%
6M Performance:
+46.31%
1Y Performance:
+42.79%
1-Day Range:
$18.77
$19.15
1-Week Range:
$18.47
$19.98
52-Week Range:
$9.03
$19.98
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
18.88 | 1.45B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.69 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.02 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.18 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.84 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.89 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Wells Fargo | Equal Weight |
| Oct-14-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Is Zymeworks Inc. stock a contrarian buyJuly 2025 Summary & Verified Momentum Watchlists - newser.com
How moving averages guide Zymeworks Inc. trading2025 Price Targets & Community Consensus Picks - newser.com
Can Zymeworks Inc. stock rebound after recent weaknessRisk Management & Free High Accuracy Swing Entry Alerts - newser.com
Will Zymeworks Inc. stock attract ESG investors2025 Growth vs Value & Fast Exit Strategy with Risk Control - newser.com
Will Zymeworks Inc. stock sustain high P E ratiosJuly 2025 Update & Fast Exit Strategy with Risk Control - newser.com
Why Zymeworks Inc. (ZA8) stock could outperform next yearWeekly Market Summary & Safe Entry Zone Identification - newser.com
Will Zymeworks Inc. stock gain from strong economyQuarterly Portfolio Report & Smart Swing Trading Techniques - newser.com
How Zymeworks Inc. (ZA8) stock performs in volatility spikesJuly 2025 Volume & Comprehensive Market Scan Reports - newser.com
How to use Fibonacci retracement on Zymeworks Inc.Quarterly Market Summary & Real-Time Volume Analysis Alerts - newser.com
Custom strategy builders for tracking Zymeworks Inc.Trade Risk Assessment & Verified Swing Trading Watchlists - newser.com
How Zymeworks Inc. (ZA8) stock stacks up against competitors2025 Key Highlights & Capital Protection Trading Alerts - newser.com
Why Zymeworks Inc. stock is in analyst buy zoneWatch List & Verified Momentum Stock Alerts - newser.com
Is Zymeworks Inc. (ZA8) stock nearing a technical breakout2025 Price Targets & Smart Allocation Stock Reports - newser.com
Is Zymeworks Inc. (ZA8) stock cheap vs fundamentalsJuly 2025 Highlights & Real-Time Buy Signal Notifications - newser.com
Zymeworks, Inc. Hits New 52-Week High at $19.98 - Markets Mojo
Zymeworks Inc. (NASDAQ:ZYME) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Zymeworks (NASDAQ:ZYME) Reaches New 52-Week HighStill a Buy? - MarketBeat
Zymeworks Inc. (ZYME) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Zymeworks stock hits 52-week high at $19.87 By Investing.com - Investing.com Australia
Applying Elliott Wave Theory to Zymeworks Inc.Market Growth Summary & Free High Accuracy Swing Entry Alerts - newser.com
How Zymeworks Inc. stock compares to market leadersJuly 2025 Fed Impact & Advanced Technical Analysis Signals - newser.com
Is now a turning point for Zymeworks Inc.Index Update & Fast Entry High Yield Stock Tips - newser.com
What sentiment indicators say about Zymeworks Inc. stock2025 Breakouts & Breakdowns & Intraday High Probability Alerts - newser.com
Zymeworks stock hits 52-week high at $19.87 - Investing.com
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
Can Zymeworks Inc. stock resist market sell offsTrend Reversal & Reliable Trade Execution Plans - newser.com
Zymeworks (ZYME) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Zymeworks Inc. (ZYME) Shareholder/Analyst CallSlideshow (NASDAQ:ZYME) 2025-10-29 - Seeking Alpha
Zymeworks (ZYME) Upgraded to Strong Buy: Here's What You Should Know - sharewise.com
Zymeworks (ZYME) Price Target Increased by 12.22% to 25.24 - Nasdaq
Is Zymeworks Inc. forming a bottoming baseJuly 2025 Closing Moves & Real-Time Buy Zone Alerts - newser.com
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):